Gossamer Bio, Inc. (GOSS)
0.1701
0.00 (0.00%)
USD |
NASDAQ |
Aug 28, 16:00
0.1724
0.00 (0.00%)
After-Hours: 20:00
Gossamer Bio Cash from Investing (Quarterly) : 42.70M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 42.70M |
| March 31, 2026 | 41.61M |
| December 31, 2025 | 73.16M |
| September 30, 2025 | 17.01M |
| June 30, 2025 | 44.13M |
| March 31, 2025 | 22.06M |
| December 31, 2024 | 53.22M |
| September 30, 2024 | -26.75M |
| June 30, 2024 | -59.11M |
| March 31, 2024 | 61.67M |
| December 31, 2023 | -14.37M |
| September 30, 2023 | -118.26M |
| June 30, 2023 | 12.94M |
| March 31, 2023 | 8.722M |
| December 31, 2022 | 8.464M |
| September 30, 2022 | -22.60M |
| June 30, 2022 | 4.679M |
| March 31, 2022 | 8.42M |
| Date | Value |
|---|---|
| December 31, 2021 | 10.44M |
| September 30, 2021 | -89.76M |
| June 30, 2021 | -50.08M |
| March 31, 2021 | 11.97M |
| December 31, 2020 | 61.10M |
| September 30, 2020 | 19.96M |
| June 30, 2020 | 106.24M |
| March 31, 2020 | 28.04M |
| December 31, 2019 | 46.93M |
| September 30, 2019 | 17.95M |
| June 30, 2019 | -13.88M |
| March 31, 2019 | -198.14M |
| December 31, 2018 | -8.681M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | 10.66M |
| December 31, 2017 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arbutus Biopharma Corp. | -1.664M |
| Kura Oncology, Inc. | 92.21M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -41.39M |
| Cash from Financing (Quarterly) | -1.181M |
| Free Cash Flow | -164.59M |
| Free Cash Flow Per Share (Quarterly) | -0.1259 |
| Free Cash Flow to Equity (Quarterly) | 121.48M |
| Free Cash Flow to Firm (Quarterly) | -38.68M |
| Free Cash Flow Yield | -380.4% |